Janus Henderson Group PLC Sells 2,893,356 Shares of Catalent, Inc. (NYSE:CTLT)

Janus Henderson Group PLC cut its holdings in shares of Catalent, Inc. (NYSE:CTLT - Free Report) by 93.5% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 201,264 shares of the company's stock after selling 2,893,356 shares during the period. Janus Henderson Group PLC owned 0.11% of Catalent worth $12,179,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in CTLT. Millennium Management LLC lifted its holdings in Catalent by 129.2% in the second quarter. Millennium Management LLC now owns 4,079,964 shares of the company's stock worth $229,416,000 after buying an additional 2,299,784 shares during the period. Alpine Associates Management Inc. lifted its stake in shares of Catalent by 3.4% in the 3rd quarter. Alpine Associates Management Inc. now owns 2,131,126 shares of the company's stock valued at $129,082,000 after purchasing an additional 69,875 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Catalent by 14.9% during the second quarter. Bank of New York Mellon Corp now owns 1,930,621 shares of the company's stock valued at $108,559,000 after purchasing an additional 250,999 shares in the last quarter. Bank of Montreal Can grew its stake in Catalent by 181.5% in the third quarter. Bank of Montreal Can now owns 1,813,167 shares of the company's stock worth $109,388,000 after purchasing an additional 1,169,044 shares during the period. Finally, Marshall Wace LLP grew its stake in Catalent by 5.1% in the second quarter. Marshall Wace LLP now owns 1,792,951 shares of the company's stock worth $100,818,000 after purchasing an additional 86,533 shares during the period.

Catalent Stock Up 0.9 %

Catalent stock traded up $0.54 during trading hours on Monday, hitting $62.37. The stock had a trading volume of 2,867,397 shares, compared to its average volume of 2,051,052. The stock's 50-day moving average price is $60.10 and its 200-day moving average price is $58.80. The stock has a market capitalization of $11.32 billion, a P/E ratio of -27.60, a price-to-earnings-growth ratio of 2.46 and a beta of 1.15. Catalent, Inc. has a 12-month low of $36.74 and a 12-month high of $62.37. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38.

Catalent (NYSE:CTLT - Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The firm had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.06 billion. During the same quarter in the previous year, the firm earned ($0.10) earnings per share. Catalent's revenue was up 4.2% on a year-over-year basis. Equities research analysts anticipate that Catalent, Inc. will post 0.84 EPS for the current fiscal year.

Insider Activity

In other news, insider David Mcerlane sold 1,994 shares of the stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total transaction of $119,580.18. Following the transaction, the insider now directly owns 36,304 shares of the company's stock, valued at $2,177,150.88. This represents a 5.21 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Michelle R. Ryan sold 2,800 shares of the business's stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the sale, the director now owns 10,835 shares of the company's stock, valued at approximately $646,849.50. This represents a 20.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 5,114 shares of company stock valued at $305,931 over the last ninety days. 0.31% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on CTLT shares. William Blair reaffirmed a "market perform" rating on shares of Catalent in a research report on Tuesday, September 3rd. Robert W. Baird restated a "neutral" rating and issued a $63.50 price objective on shares of Catalent in a report on Tuesday, September 24th. StockNews.com raised shares of Catalent from a "sell" rating to a "hold" rating in a research note on Monday, December 2nd. Finally, Baird R W cut Catalent from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, September 24th. Eight analysts have rated the stock with a hold rating, According to MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $63.40.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.